Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.46 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.46 |
| ▸ | DPP4 | P27487 | 2/20 | 0.46 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11433347 | 0.90 | POLB (0.61) | POLBL3MBTL1CHRM2CHRM4CHRM1 | |
| SCHEMBL11434077 | 0.85 | POLB (0.55) | POLBL3MBTL1CHRM2CHRM4CHRM1 | |
| SCHEMBL30484011 | 0.83 | POLB (0.58) | POLBL3MBTL1CHRM2CHRM4CHRM1 | |
| SCHEMBL9061218 | 0.83 | POLB (0.58) | POLBL3MBTL1CHRM2CHRM4CHRM1 | |
| SCHEMBL24943342 | 0.82 | POLB (0.61) | POLBL3MBTL1CHRM2CHRM4CHRM1 | |
| SCHEMBL24943268 | 0.82 | POLB (0.61) | POLBL3MBTL1CHRM2CHRM4CHRM1 | |
| SCHEMBL13066635 | 0.82 | POLB (0.56) | POLBL3MBTL1CHRM2CHRM4CHRM1 | |
| SCHEMBL2214414 | 0.81 | L3MBTL1 (0.54) | POLBL3MBTL1MEN1KMT2A | |
| SCHEMBL2220842 | 0.81 | L3MBTL1 (0.54) | POLBL3MBTL1MEN1KMT2A | |
| SCHEMBL2220837 | 0.81 | L3MBTL1 (0.54) | POLBL3MBTL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3604533-A1 | SITE-SPECIFIC DELIVERY OF NUCLEIC ACIDS BY COMBINING TARGETING LIGANDS WITH ENDOSOMOLYTIC COMPONENTS | Arbutus Biopharma Corporation (CA) | 2020-02-05 | — | — | EP | disclosed |